INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 78 filers reported holding INOZYME PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,639,057 | -15.5% | 628,347 | +12.0% | 0.00% | – |
Q2 2023 | $3,123,890 | +456.0% | 560,842 | +472.0% | 0.00% | – |
Q1 2023 | $561,855 | +250.4% | 98,055 | -35.8% | 0.00% | – |
Q4 2022 | $160,346 | -21.8% | 152,710 | +100.0% | 0.00% | – |
Q3 2022 | $205,000 | -12.4% | 76,355 | +55.7% | 0.00% | – |
Q2 2022 | $234,000 | -69.7% | 49,055 | -74.0% | 0.00% | – |
Q1 2022 | $773,000 | -39.4% | 189,005 | +1.0% | 0.00% | – |
Q4 2021 | $1,276,000 | -41.5% | 187,102 | -0.6% | 0.00% | – |
Q3 2021 | $2,182,000 | -24.6% | 188,267 | +10.8% | 0.00% | – |
Q2 2021 | $2,895,000 | +10.6% | 169,889 | +28.5% | 0.00% | – |
Q1 2021 | $2,618,000 | +7.9% | 132,219 | +12.5% | 0.00% | – |
Q4 2020 | $2,427,000 | +30.8% | 117,579 | +66.6% | 0.00% | – |
Q3 2020 | $1,856,000 | – | 70,585 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18,878,374 | 7.53% |
CHI Advisors LLC | 1,270,027 | $5,334,112 | 2.11% |
Samsara BioCapital, LLC | 1,562,500 | $6,562,500 | 2.01% |
Affinity Asset Advisors, LLC | 1,379,852 | $5,795,378 | 1.63% |
Sofinnova Investments, Inc. | 4,280,308 | $17,977,294 | 1.13% |
SPHERA FUNDS MANAGEMENT LTD. | 1,234,907 | $5,186,609 | 0.94% |
Octagon Capital Advisors LP | 1,300,000 | $5,460,000 | 0.84% |
NEA Management Company, LLC | 2,437,689 | $10,238,294 | 0.79% |
Knott David M Jr | 454,008 | $1,907 | 0.73% |
Rock Springs Capital Management LP | 3,681,174 | $15,460,931 | 0.41% |